ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 1044

Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain

Spondyloarthritis Including PsA – Treatment Poster II: Mixed

9:00AM-10:30AM: Abstract Number: 0734

Comfort Levels and Practice Patterns for Osteoporosis-Related Care Among Persons Living with HIV in Peru: A National Physician Survey

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0622

Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0887

Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 1010

Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 1012

Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0659

Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0819

Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0857

Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs for Classification in Juvenile Spondyloarthritis

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0945

Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0956

Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0937

Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0600

Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0667

Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0895

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

«Previous Page
1
…
7
8
9
10
11
…
71
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].